2023
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani A, Alexander J, Sumner C, Pine J, Gross L, Raison C, Aaronson S, Baron D. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal Of Psychiatric Practice 2023, 29: 345-353. PMID: 37678363, DOI: 10.1097/pra.0000000000000729.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnxietyAnxiety DisordersDepressive Disorder, Treatment-ResistantHallucinogensHumansPsilocybin
2022
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorder
2021
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdolescentAgedAnxiety DisordersDepressive Disorder, MajorHumansSelective Serotonin Reuptake InhibitorsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequences
2018
Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine.
Garakani A. Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine. The Primary Care Companion For CNS Disorders 2018, 20 PMID: 30550646, DOI: 10.4088/pcc.18l02316.Peer-Reviewed Case Reports and Technical Notes
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2008
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist
2006
Neurobiology of anxiety disorders and implications for treatment.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Annals Of Global Health 2006, 73: 941-9. PMID: 17195879.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-traumatic stress disorderCognitive behavioral therapyFear conditioningUnconditioned stimulusAnxiety disordersPartial NMDA agonistFear inhibitionFear extinctionTraumatic memoriesFear circuitryFear responsesPavlovian conditioningBehavioral therapyStress disorderSpecific phobiaNew learningAmygdala pathwayD-cycloserineAnti-anxiety treatmentPanic disorderPreliminary evidenceStimuliMemoryN-methyl-D-aspartate antagonistsNeurobiology